Literature DB >> 18632008

Challenges in clinical research on Alzheimer's disease: Leon Thal's legacy.

Ronald C Petersen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 18632008      PMCID： PMC2699404          DOI： 10.1016/j.jalz.2007.11.004

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN： 1552-5260            Impact factor:   21.566


× No keyword cloud information.
  18 in total

1.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment.

Authors:  C R Jack; R C Petersen; Y C Xu; P C O'Brien; G E Smith; R J Ivnik; B F Boeve; S C Waring; E G Tangalos; E Kokmen
Journal:  Neurology       Date:  1999-04-22       Impact factor: 9.910

Review 2.  Mild cognitive impairment clinical trials.

Authors:  Ronald C Petersen
Journal:  Nat Rev Drug Discov       Date:  2003-08       Impact factor: 84.694

3.  The apolipoprotein E epsilon4 allele and incident Alzheimer's disease in persons with mild cognitive impairment.

Authors:  Neelum T Aggarwal; Robert S Wilson; Todd L Beck; Julia L Bienias; Elizabeth Berry-Kravis; David A Bennett
Journal:  Neurocase       Date:  2005-02       Impact factor: 0.881

4.  Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.

Authors:  Alexander Drzezga; Timo Grimmer; Matthias Riemenschneider; Nicola Lautenschlager; Hartwig Siebner; Panagiotis Alexopoulus; Satoshi Minoshima; Markus Schwaiger; Alexander Kurz
Journal:  J Nucl Med       Date:  2005-10       Impact factor: 10.057

5.  Vitamin E and donepezil for the treatment of mild cognitive impairment.

Authors:  Ronald C Petersen; Ronald G Thomas; Michael Grundman; David Bennett; Rachelle Doody; Steven Ferris; Douglas Galasko; Shelia Jin; Jeffrey Kaye; Allan Levey; Eric Pfeiffer; Mary Sano; Christopher H van Dyck; Leon J Thal
Journal:  N Engl J Med       Date:  2005-04-13       Impact factor: 91.245

6.  Neuropathologic substrate of mild cognitive impairment.

Authors:  William R Markesbery; Frederick A Schmitt; Richard J Kryscio; Daron G Davis; Charles D Smith; David R Wekstein
Journal:  Arch Neurol       Date:  2006-01

7.  A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment.

Authors:  Leon J Thal; Steven H Ferris; Louis Kirby; Gilbert A Block; Christopher R Lines; Eric Yuen; Christopher Assaid; Michael L Nessly; Barbara A Norman; Christine C Baranak; Scott A Reines
Journal:  Neuropsychopharmacology       Date:  2005-06       Impact factor: 7.853

8.  Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals.

Authors:  R C Petersen; G E Smith; R J Ivnik; E G Tangalos; D J Schaid; S N Thibodeau; E Kokmen; S C Waring; L T Kurland
Journal:  JAMA       Date:  1995-04-26       Impact factor: 56.272

9.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.

Authors:  Oskar Hansson; Henrik Zetterberg; Peder Buchhave; Elisabet Londos; Kaj Blennow; Lennart Minthon
Journal:  Lancet Neurol       Date:  2006-03       Impact factor: 44.182

10.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.

Authors:  William E Klunk; Henry Engler; Agneta Nordberg; Yanming Wang; Gunnar Blomqvist; Daniel P Holt; Mats Bergström; Irina Savitcheva; Guo-feng Huang; Sergio Estrada; Birgitta Ausén; Manik L Debnath; Julien Barletta; Julie C Price; Johan Sandell; Brian J Lopresti; Anders Wall; Pernilla Koivisto; Gunnar Antoni; Chester A Mathis; Bengt Långström
Journal:  Ann Neurol       Date:  2004-03       Impact factor: 10.422
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.